Analysis of the NET G3 of lungs

#4063

Introduction: There are still a lot of questions regarding NET G3 subgroup and especially with lungs origin. Neuroendocrine neoplasms account for 20% of lung primary with only 2% for well-differentiated tumors.

Aim(s): Evaluation of the prevalence of SSTR in the NET G3 of lungs, overall survival, progression free survival for the 1st line treatment.

Materials and methods: 20 patients (pts) with median age of 50 (23-73). 14 pts (70%) had stage IV disease, 1 (5%) with stage III, 4 (20%) – II and 1 with I stage. Median ki-67 was 38% (23-55%). 75% were female. Progression-free (PFS) and overall survival (OS) were accessed by Kaplan-Meier survival analysis, IBM SPSS Statistics v.26. Median OS in whole group was 31 months (m) and mPFS was 12 m.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Markovich A, Delektorskaya V, Yemelyanova G, Kuznetsova A,

Keywords: NET, G3, SSTR, somatostatin analogues, SSA, lung,